Atezolizumab, has recently been approved by the EMA as monotherapy for the “first-line treatment of adult patients with metastatic NSCLC with PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating IC and who do not have EGFR mutant or ALK-positive” [23]. Here, ALK is linked to neoplasm.